The story
An engineered virus injected directly into tumours has halted the progression of inoperable pancreatic cancer in three patients in a University of Minnesota Phase I trial. The treatment uses a genetically engineered adenovirus, RGDCRAdCOX2F (trial NCT06693986), and all three patients were still alive with stable disease more than six months after treatment; in the fall 2026 follow-up, one had reached 15 months of disease control. The findings were presented at the ASGCT meeting in May 2026. The caveats are substantial: the trial involved only three patients, had no control group, and the results have not yet appeared as a full peer-reviewed paper. 'Halted' here means stable disease — the cancer stopped growing — not a cure or tumour shrinkage.Latest development
no keepalive from any source this round (no Lobsters/Techmeme/YouTube trace)